Table 4 Cox multivariate analysis separately shown for patients belonging to the two groups of treatment 1
From: Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision
| Â | Surgery alone | 5-Fu therapy | |||
|---|---|---|---|---|---|
HR | (p) | HR | (p) | ||
Clinical-pathological features | Age | 0.66 | (0.6) | 3.43 | (0.2) |
Sex | 0.99 | (1.0) | 1.34 | (0.8) | |
Tumour location | 2.09 | (0.5) | 1.36 | (0.7) | |
Tumour grade | 0.71 | (0.7) | 1.99 | (0.7) | |
Depth of tumour invasion | 5.22 | (0.2) | 1.26 | (0.9) | |
Lymphovascular invasion | 0.50 | (0.4) | 0.27 | (0.2) | |
Large veins invasion | 2.14 | (0.4) | 0.40 | (0.3) | |
Tumour inflammatory response | 1.30 | (0.6) | 0.53 | (0.1) | |
Tumour border configuration | 4.91 | (0.2) | 2.18 | (0.6) | |
Molecular parameters | MMR system | 0.15 | (0.2) | 37.85 | (0.04) |
CIMP | 0.67 | (0.6) | 0.17 | (0.05) | |
TS by mRNA | 6.08 | (0.04) | 0.54 | (0.2) | |
TS by IHC | 0.35 | (0.1) | 2.03 | (0.4) | |
| Â | TP53 | 0.71 | (0.7) | 0.63 | (0.6) |
| Â | CTNNB1activation grades | 0.35 | (0.1) | 1.60 | (0.5) |
|  | BRAF c.1799 T > A | 2.67 | (0.3) | 2.99 | (0.3) |